Celldex Therapeutics (CLDX) Operating Expenses (2010 - 2026)

Celldex Therapeutics' Operating Expenses history runs 17 years deep, the most recent figure standing at $84.4 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 33.13% year-over-year to $84.4 million in Q1 2026; TTM through Mar 2026 was $309.9 million, a 37.89% increase from a year earlier, with the FY2025 full-year figure at $288.9 million, up 42.96% from the prior year.
• Operating Expenses retreated to $84.4 million in Q1 2026 per CLDX's latest filing, from $87.3 million in the prior quarter.
• Across five years, Operating Expenses topped out at $87.3 million in Q4 2025 and bottomed at $23.4 million in Q1 2022.
• The 5-year median for Operating Expenses is $48.8 million (2024), against an average of $50.3 million.
• Across the five-year window, Operating Expenses jumped 116.07% in 2022 and slipped 8.44% in 2023, its largest moves.
• Year by year, Operating Expenses stood at $29.5 million in 2022, then jumped by 75.46% to $51.8 million in 2023, then increased by 10.52% to $57.2 million in 2024, then surged by 52.57% to $87.3 million in 2025, then retreated by 3.24% to $84.4 million in 2026.
• Per Business Quant, the three latest CLDX Operating Expenses figures stand at $84.4 million (Q1 2026), $87.3 million (Q4 2025), and $73.6 million (Q3 2025).